Further evidence for favorable cost-effectiveness of elderly influenza vaccination

References

• Wilschut J, McElhaney JM. Rapid Reference Influenza. Mosby, Elsevier Science, 1–216.
   Google Scholar
• Nicholson KG, Wood JM, Zambon M. Influenza. Lancet362, 1733–1745 (2003).
   PubMed Web of Science ®Google Scholar
• Zimmerman R. Lowering the age for routine influenza vaccination. Am. Fam. Physician 60, 2061–2066 (2005).
   Google Scholar
• Postma MJ, Baltussen RMPM, Heijnen M-LA, de Jong-van den Berg LTW, Jager JC. Pharmacoeconomics of influenza vaccination in the elderly; reviewing the available evidence. Drugs Aging 17, 217–227 (2000).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Jansema P, van Genugten ML, Heijnen MLA, Jager JC, de Jong-van den Berg LTW. Pharmacoeconomics of vaccinating healthy working adults against influenza; reviewing the available evidence. Drugs62, 1013–1024 (2002).
   PubMed Web of Science ®Google Scholar
• Foucher RA, Schneeberger PM, Rozendaal FW et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl Acad. Sci. USA 101, 1356–1361 (2004).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global agenda on influenza – adopted version. Part I. Wkly Epidemiol. Rec. 77, 179–182. Part II, 191–196 (2002).
   PubMedGoogle Scholar
• Wood JM, Williams MS. History of inactivated influenza vaccines. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, UK, 317–323 (1998).
   Google Scholar
• World Health Organization. Influenza vaccines. Wkly Epidemiol. Rec. 75, 281–288; 77, 230–239 (2002).
   Google Scholar
• Centers for Disease Control and Prevention. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR51(RR 3) (2002).
   Google Scholar
• Van Essen GA, Forleo E, Palache AM, Fedson DS. Influenza vaccination in 2000: vaccination recommendations and vaccine use in 50 developed and developing countries. Vaccine21, 1780–1785 (2003).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global distribution of influenza vaccines, 2000 2003. Wkly Epidemiol. Rec. 79, 366–367 (2004).
   PubMedGoogle Scholar
• College voor Zorgverzekeringen (CvZ). Nationaal Programma Grieppreventie: het success van de griepprik. CvZ, Diemen (2003).
   Google Scholar
• Stöhr K, Esveld M. Will vaccines be available for the next influenza pandemic? Science306, 2195–2196 (2004).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Bos JM, van Gennep M et al. Economic evaluation of influenza vaccination; assessment for the Netherlands. Pharmacoeconomics16(Suppl. 1), 33–40 (2000).
   Google Scholar
• Nichol KL, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics16(Suppl. 1), 63–71 (1999).
   PubMed Web of Science ®Google Scholar
• Weaver M, Krieger J, Castorina J, Walls M, Ciske S. Cost–effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch. Intern. Med. 161, 111–120 (2001).
   PubMedGoogle Scholar
• Fitzner KA, Shortridge KF, µghee SM, Hedley AJ. Cost–effectiveness study on influenza prevention in Hong Kong. Health Policy 56, 215–234 (2001).
   PubMed Web of Science ®Google Scholar
• Gasparini R, Lucioni C, Lai P et al. Cost–benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine B50–B54 (2002).
   PubMedGoogle Scholar
• Wang C-S, Wang S-T, Chou P. Efficacy and cost–effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine20, 2494–2499 (2002).
   PubMed Web of Science ®Google Scholar
• Wangsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J. Med. Assoc. Thai. 86, 497–508 (2003).
   PubMedGoogle Scholar
• Allsup S, Haycox A, Regan M, Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years? A randomised controlled trial. Vaccine23, 639–645 (2004).
   PubMed Web of Science ®Google Scholar
• Hak E, Buskens E, van Essen GA et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions. Arch. Intern. Med. 165, 274–280 (2005).
   PubMedGoogle Scholar
• Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost–effectiveness and public policy. JAMA 249, 3189–3195 (1983).
   PubMed Web of Science ®Google Scholar
• Patriarca PA, Arden NH, Koplan JP et al. Prevention and control of type A influenza infections in nursing homes: benefits and costs of four approaches using vaccination and amantidine. Ann. Intern. Med. 107, 732–740 (1987).
   PubMed Web of Science ®Google Scholar
• Helliwel BE, Drummond MF. The costs and benefits of preventing influenza in Ontario’s elderly. Can. J. Publ. Health79, 175–180 (1988).
   PubMed Web of Science ®Google Scholar
• Maucher JM, Gambert SM. Cost-effective analysis of influenza vaccination in the elderly. Age13, 81–85 (1990).
   Google Scholar
• Grabenstein JD, Hartzema AG, Guess HA et al. Community pharmacists as immunisation advocates: cost–effectiveness of a cue to influenza vaccination. Med. Care 30, 503–513 (1992).
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Bennet MD, Hornbrook MC et al. Influenza vaccination programs for elderly persons: cost–effectiveness in a health maintenance organisation. Ann. Intern. Med. 121, 947–952 (1994).
   PubMed Web of Science ®Google Scholar
• Scott WG, Scott HM. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics9, 51–60 (1996).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Wuerenma RN, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch. Intern. Med. 158, 1769–1776 (1998).
   PubMed Web of Science ®Google Scholar
• Hak E, van Essen GA, Buskens E et al. Is immunising all patients with chronic lung disease in the community against influenza cost-effective? Evidence from a general practice-based clinical prospective cohort study in Utrecht, The Netherlands. J. Epidemiol. Commun. Health 52, 120–125 (1998).
   PubMed Web of Science ®Google Scholar
• Postma MJ. Pharmacoeconomic research. Pharm. World Sci. 25, 245–246 (2003).
   PubMedGoogle Scholar
• Baltussen R, Reinders A, Sprenger MJW et al. Estimating influenza-related hospitalizations in The Netherlands. Epidemiol. Infect. 121, 129–138 (1998).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Jansema P, Scheijbeler HWKFH, van Genugten MLL. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine 23, 5365–5371 (2005).
   Google Scholar
• Postma MJ, Heijnen M-LA, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics19, 215–222 (2001).
   PubMed Web of Science ®Google Scholar
• Van Genugten MLL, Heijnen M-LA, Jager JC. Pandemic influenza and healthcare demand in The Netherlands. Emerging Infect. Dis.9, 531–538 (2003).
   PubMed Web of Science ®Google Scholar
• Office of Technology Assessment. Cost effectiveness of influenza vaccination. Congressional Board of the 97th Congress, Washington DC, USA (1981).
   Google Scholar
• Patriarca PA, Weber JA, Parker RA et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 253, 1136–1139 (1985).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. Public health burden of vaccine-preventable diseases among adults: standards for adult immunisation practice. Morb. Mortal. Wkly Rep. 39, 725–729 (1990).
   PubMedGoogle Scholar
• Centers for Disease Control. Prevention and control of influenza. JAMA 260, 318–322 (1988).
   PubMedGoogle Scholar
• Ruben FL. Prevention of influenza in the elderly. J. Am. Geriatr. Soc. 30, 577–580 (1982).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Margolis KL, Wourenma J et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331, 778–784 (1994).
   PubMed Web of Science ®Google Scholar
• Gross PA, Hermogenes AW, Sacks HS et al. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann. Intern. Med. 123, 518–527 (1995).
   PubMed Web of Science ®Google Scholar
• Govaert TME, Thijs CTMCN, Masurel N, Sprenger MJW, Dinant GJ, Knottnerus JA. The efficacy of the influenza vaccination in elderly individuals: a randomized double-blind placebo-controlled trial. JAMA 272, 1661–1665 (1994).
   PubMed Web of Science ®Google Scholar
• Office of Technology Assessment. Cost-effectiveness of influenza vaccination. Washington DC: Conressional Board of the 97th Congress 1981.
   Google Scholar
• Bos JM, Postma MJ. Using pharmacoeconomics for policy making: is rational decision making enhanced by applying thresholds for cost-effectiveness. Expert Rev. Pharmacoeconomics Outcomes Res.4, 247–250 (2004).
   PubMedGoogle Scholar
• Tolley K, Postma MJ. Pharmacoeconomics and market access in Europe; case studies in the UK and the Netherlands. Value in Health (2006) (In Press).
   Google Scholar
• Wood SC, Nguyen VH, Schmidt C. Economic evaluation of influenza in the elderly. Impact on public health policy. Dis. Manage. Health Outcomes 8, 273–285 (2000).
   Google Scholar
• Nichol KL, Goodman M. The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years. Pharmacoeconomics16(Suppl. 1), 63–71 (1999).
   PubMed Web of Science ®Google Scholar
• Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine20, 2562–2578 (2002).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Mugford M, Gray A, Demicheli V. An exercise in the feasibility of carrying out secondary economic analyses. Health Economics5, 155–165 (1996).
   Google Scholar
• Voordouw BCG, van der Linden PD, Simonian S et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-related morbidity. Arch. Intern. Med. 163, 1089–1094 (2003).
   PubMedGoogle Scholar
• Voordouw BCG, Sturkenboom MCJM, Dieleman JP et al. Annual revaccination against influenza and mortality risk in community-dwelling elderly persons. JAMA 292, 2089–2095 (2004).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Heijnen M-LA, de Vries R, Beutels Ph, Jager JC. Splenectomi.e., en pneumokokkenvaccinati.e. Nederlands Tijdschrift voor Geneeskunde147, 1141–1142 (2003).
   PubMedGoogle Scholar
• Postma MJ, Heijnen M-LA, Beutels Ph, Jager JC. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands. Expert Rev. Vaccines 2, 477–482 (2003).
   PubMedGoogle Scholar
• Melegaro A, Edmunds WJ. The 23 valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur. J. Epidemiol. 19, 365–375 (2004).
   PubMed Web of Science ®Google Scholar
• Honkanen PO, Keistinen T, Miettinen L et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years and older. Vaccine17, 2493–2500 (1999).
   PubMed Web of Science ®Google Scholar
• Christenson B, Lundbergh P, Hedlund J, Örtqvist Å. Effects of a large-scale intervention with influenza and 23 valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet357, 1008–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Christenson B, Hedlund J, Lundbergh P, Örtqvist Å. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur. Respir. J. 23, 363–368 (2004).
   PubMed Web of Science ®Google Scholar
• Lynd LD, Goeree R, O’Brien BJ. Antiviral agents for influenza; a comparison of cost-effectiveness data. Pharmacoeconomics23, 1083–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Turner D, Wailoo A, Nicholson A et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. National Institute of Clinical Excellence (NICE) Leicester, UK (2002).
   Google Scholar
• Risebrough NA, Bowles SK, Simor AE, µgeer A, Oh PI. Economic evaluation of oseltamivir phosphate for postexposure prophylaxis of influenza in long-term care facilities. J. Am. Geriatr. Soc. 53, 444–450 (2005).
   PubMed Web of Science ®Google Scholar
• Glezen WP, Greenberg SB, Atmar RL et al. Impact of respiratory virus infections on persons with chronic underlying conditions. J. Am. Med. Assoc.283, 499–505 (2000).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Influenza vaccines. Wkly Epidemiol. Rec. 77, 230–239 (2002).
   PubMedGoogle Scholar
• Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine21, 1769–1775 (2003).
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr. Infect. Dis. J. 20, 733–740 (2001).
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Edwards KM. Influenza vaccines in children. Semin. Pediatr. Infect. Dis. 13, 174–181 (2002).
   PubMedGoogle Scholar
• Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics106, 973–976 (2000).
   PubMed Web of Science ®Google Scholar
• Nichol KL. Efficacy/clinical effectiveness of inactivated influenza virus vaccines in adults. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science, UK, 358–372 (1998).
   Google Scholar
• Nichol KL, Lind A, Margolis KL et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 333, 889–893 (1995).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine21, 2207–2217 (2003).
   PubMed Web of Science ®Google Scholar